{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Cohort+3",
    "query": {
      "intervention": "Part 1, Cohort 3"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 931,
    "total_pages": 94,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Cohort+3&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T16:36:56.077Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01654380",
      "title": "A Study of LY2605541 Versus Insulin Glargine on Blood Sugar",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Diabetes Mellitus, Type 1"
      ],
      "interventions": [
        {
          "name": "LY2605541",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2012-07",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2019-03-08",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01654380"
    },
    {
      "nct_id": "NCT03486990",
      "title": "Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Celiac Disease"
      ],
      "interventions": [
        {
          "name": "TIMP-GLIA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 23,
      "start_date": "2018-01-23",
      "completion_date": "2019-07-22",
      "has_results": true,
      "last_update_posted_date": "2020-06-05",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486990"
    },
    {
      "nct_id": "NCT02361346",
      "title": "Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Hodgkin's B-cell Lymphoma",
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "Small Lymphocytic Leukemia",
        "Diffuse Large B Cell Lymphoma",
        "Blood Cancer",
        "Hematological Malignancy"
      ],
      "interventions": [
        {
          "name": "MT-3724 Phase 1",
          "type": "DRUG"
        },
        {
          "name": "MT-3724 Phase 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2015-02",
      "completion_date": "2021-03-22",
      "has_results": true,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Whittier, California • Jacksonville, Florida + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02361346"
    },
    {
      "nct_id": "NCT04363242",
      "title": "A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Epithelial Carcinoma",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SYN125",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SYN004",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Synermore Biologics Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2020-04-09",
      "completion_date": "2023-09-30",
      "has_results": false,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 4,
      "location_summary": "Fairway, Kansas • Brownstown, Michigan • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Brownstown",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04363242"
    },
    {
      "nct_id": "NCT00352443",
      "title": "S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2006-09",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00352443"
    },
    {
      "nct_id": "NCT04994106",
      "title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD5462",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 98,
      "start_date": "2021-07-27",
      "completion_date": "2022-09-20",
      "has_results": false,
      "last_update_posted_date": "2022-10-05",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04994106"
    },
    {
      "nct_id": "NCT04634552",
      "title": "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematological Malignancies"
      ],
      "interventions": [
        {
          "name": "Talquetamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 510,
      "start_date": "2021-02-01",
      "completion_date": "2029-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04634552"
    },
    {
      "nct_id": "NCT07502885",
      "title": "Deep Phenotyping Gait Deficits in Orthopedic Manifestations of Pediatric Cancer Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sarcoma, Bone",
        "Sarcoma, Soft Tissue",
        "Gait Disorder"
      ],
      "interventions": [
        {
          "name": "Lab based 3D Gait Assessment",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Wearable Inertial Sensors (In Lab and Remote)",
          "type": "DEVICE"
        },
        {
          "name": "Functional Testing & Patient Reported Outcomes",
          "type": "OTHER"
        },
        {
          "name": "Remote Wearable Sensor Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "5 Years to 20 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-06-16",
      "completion_date": "2032-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07502885"
    },
    {
      "nct_id": "NCT03094832",
      "title": "Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome"
      ],
      "interventions": [
        {
          "name": "Miransertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2017-05-16",
      "completion_date": "2022-04-11",
      "has_results": true,
      "last_update_posted_date": "2023-04-13",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 6,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03094832"
    },
    {
      "nct_id": "NCT07027514",
      "title": "A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "tolododekin alfa",
          "type": "DRUG"
        },
        {
          "name": "Cetrelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ankyra Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-10-22",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-09-21T16:36:56.077Z",
      "location_count": 11,
      "location_summary": "Coral Gables, Florida • Jacksonville, Florida • Peoria, Illinois + 8 more",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027514"
    }
  ]
}